Yuqin Song, MD, PhD
The BTK inhibitor zanubrutinib (BGB-3111) continued to show promising activity in patients with relapsed/refractory mantle cell lymphoma (MCL), with an overall response rate (ORR) of 84.7%, according to updated phase II findings presented at the 15th International Conference on Malignant Lymphoma.
In China, we have bendamustine, [which] just got approved by the CDA. [We] also have lenalidomide (Revlimid), [which is a good choice for frail patients]. We also have several different CAR T-cell therapy products in our center.
Song Y, Zhou K, Zou D et al. Zanubrutinib in Patients with Relapsed/Refractory Mantle Cell Lymphoma. Presented at: 15th International Conference on Malignant Lymphoma Palazzo dei Congressi; June 18-22, 2019; Lugano, Switzerland.
... to read the full story